Metsera gains on early-stage results of weight loss drug

Shares of drug developer Metsera MTSR.O rise 17.28% to $32.24 premarket

Co says its experimental weight loss drug, MET-233i, hit up to 8.4% weight loss, on placebo adjusted basis, at 36 days in a small, early-stage trial

MET-233i, a long-acting injectable monthly amylin analogue, is being developed as a standalone treatment and in combination with another experimental GLP-1 drug MET-097i

The trial studied MET-233i in 80 participants with overweight or obesity without type 2 diabetes

Up to last close, stock up 3.7% since it went public in January